Paul Pavlou has been named as the dean of C. T. Bauer College of Business at the University of Houston. Courtesy of UH

Earlier this year, the University of Houston named a new dean for its C.T. Bauer College of Business. Paul Pavlou officially started his position on July 1, and, even though he has only a few days under his belt at UH, the new dean has a long career in education.

Most recently, Pavlou served as senior associate dean at Temple University within its business program and specializing in data analytics for business. Pavlou also has ties to Houston, as he received his bachelor's from Rice University after receiving a Fulbright Scholarship.

"My life was transformed by higher education," Pavlou says. "So, I feel the need to give back in terms of helping other students — especially of modest means like myself to do well in life and get a good job."

Pavlou has a lot on his plate entering the fall semester. He plans to continue enhancing the college's programs and faculty, while also continue the school's effort to bring in innovation and industry.

The new dean spoke with InnovationMap about what all he sees in Bauer's future.

InnovationMap: How has the first few days on the job been?

Paul Pavlou: So far it's been very exciting. There's so many opportunities for the Bauer College in innovation and technology in new areas that we're considering such health care, analytics, some of the existing areas in energy. So, the goal in my first few days is to talk to as many stakeholders as possible. Try to get to know our existing practices internally, what the opportunities are in the city, and of course, broadly, nationally, internationally. And accordingly, the plan is to see how we can focus on this needs of the industry, how we can create cutting edge programs and prepare the next generation of the workforce, obviously for the city of Houston or the state of Texas nationally and even that globally.

IM: What are some things on your plate that you hope to bring to the college?

PP: In general, one of the areas that I'd like to see us moving into as a college is the digital learning online and how we can do that in a way that it's convenient and flexible for students. Also at the same time, not only maintain the quality of traditional instruction, but also using technology intelligently to provide an even higher quality, more interactive experience for students.

The second thing that I'm very passionate about as well as the notion of experiential learning. I think students should learn from experience and learn by doing. So I would like to see how we can improve this at this college. I'm very happy to report that Bauer has very strong connections to industry, but I would like to make it an even a very strong proposition for the entire college — making sure that, you know, different courses that have an experiential component such as project or working closely with industry.

IM: How is Bauer focusing on the needs the city has for an emerging workforce?

PP: I think increasingly I find and identify more of the city's needs, but I think one of them is the idea of the analytics space and how to use the data. And that's across the board. I talk to people in health care and they say that health care analytics and using data in hospitals is a very important aspect.

More broadly, cutting edge technology is something that is very important not only the city of Houston but beyond. So. we're discussing this idea of artificial intelligence, and how we can play a role in this in a very important emerging area.

One of the things that I would like to see more of is for the University of Houston to work more closely with the business community. We're trying to develop partnerships with the greater Houston partnership and to see what they need as an industry, perhaps for the next generation of workforce.

IM: What role do you see the school playing in the city's innovation ecosystem?

PP: I think we can play a multiple roles. We're an educational organization, so we train the students. We want make sure that through our degrees and offerings have executive programs, and that we satisfy the need for competence and skills needed. And that's why I want us to be on the cutting edge, not only now but in the next five or 10 years.

Second, through our research and through our connections to industry, I want us to be cutting edge in terms of projects and basic research we can actually provide, whether it's analytics, artificial intelligence, or energy. Through our centers and our research, we have world class research faculty in the college. I want us to be out there and to start with the major challenges and help them.

IM: How is the college working with other programs within the university?

PP: One thing I'd like to specify, is that Bauer is obviously a college of business, but I want to take a very broad, multidisciplinary perspective and be very collaborative with the college of medicine, engineering, and nursing. And the idea is to be more open in terms of partnerships with different areas that innovation and new ideas may come into play and provide the business and entrepreneurship components to bring these ideas to market.

------

Portions of this interview have been edited.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.